M. Chan Et Al. , "Enantiomerically pure beta-dipeptide derivative induces anticancer activity against human hormone-refractory prostate cancer through both PI3K/Akt-dependent and -independent pathways," ONCOTARGET , vol.8, no.57, pp.96668-96683, 2017
Chan, M. Et Al. 2017. Enantiomerically pure beta-dipeptide derivative induces anticancer activity against human hormone-refractory prostate cancer through both PI3K/Akt-dependent and -independent pathways. ONCOTARGET , vol.8, no.57 , 96668-96683.
Chan, M., Yu, C., Hsu, J., Leu, W., Chan, S., Hsu, L., ... Liu, S.(2017). Enantiomerically pure beta-dipeptide derivative induces anticancer activity against human hormone-refractory prostate cancer through both PI3K/Akt-dependent and -independent pathways. ONCOTARGET , vol.8, no.57, 96668-96683.
Chan, Mei-Ling Et Al. "Enantiomerically pure beta-dipeptide derivative induces anticancer activity against human hormone-refractory prostate cancer through both PI3K/Akt-dependent and -independent pathways," ONCOTARGET , vol.8, no.57, 96668-96683, 2017
Chan, Mei-Ling Et Al. "Enantiomerically pure beta-dipeptide derivative induces anticancer activity against human hormone-refractory prostate cancer through both PI3K/Akt-dependent and -independent pathways." ONCOTARGET , vol.8, no.57, pp.96668-96683, 2017
Chan, M. Et Al. (2017) . "Enantiomerically pure beta-dipeptide derivative induces anticancer activity against human hormone-refractory prostate cancer through both PI3K/Akt-dependent and -independent pathways." ONCOTARGET , vol.8, no.57, pp.96668-96683.
@article{article, author={Mei-Ling Chan Et Al. }, title={Enantiomerically pure beta-dipeptide derivative induces anticancer activity against human hormone-refractory prostate cancer through both PI3K/Akt-dependent and -independent pathways}, journal={ONCOTARGET}, year=2017, pages={96668-96683} }